Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. - Wikidata - awgldk - TriplyDB

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

http://www.wikidata.org/entity/Q33959857

about

Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy Advanced endoscopic imaging of indeterminate biliary strictures Diagnosis of cholangiocarcinoma.Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma Hepatobiliary complications of inflammatory bowel disease.Clinical evaluation, imaging studies, indications for cytologic study and preprocedural requirements for duct brushing studies and pancreatic fine-needle aspiration: The Papanicolaou Society of Cytopathology Guidelines.Expression of sialyl Lewis(a) relates to poor prognosis in cholangiocarcinoma.New insights on cholangiocarcinoma.Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma Circulating CYFRA 21-1 is a Specific Diagnostic and Prognostic Biomarker in Biliary Tract Cancer.Management of primary sclerosing cholangitis: conventions and controversies Systematic review with meta-analysis: endoscopic retrograde cholangiopancreatography-based modalities for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis.Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat Differentiation of malignant and benign proximal bile duct strictures: the diagnostic dilemma.Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009 Treatment options for primary sclerosing cholangitis.Primary sclerosing cholangitis: overview and update.Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis.Evolving concepts in primary sclerosing cholangitis.Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. Part I: diagnosis-clinical staging and pathology.Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma.Clinical evaluation, imaging studies, indications for cytologic study, and preprocedural requirements for duct brushing studies and pancreatic FNA: the Papanicolaou Society of Cytopathology recommendations for pancreatic and biliary cytology.A common genetic variant of fucosyltransferase 2 correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis.The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience.Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis.Increased serum levels of carbohydrate antigen 19-9 and outcomes in primary sclerosing cholangitis patients without cholangiocarcinoma.Current management of cholangiocarcinoma.Optimizing the detection of biliary dysplasia in primary sclerosing cholangitis before liver transplantation.A very rare cause of markedly elevated CA 19.9: Autoimmune hepatitis.CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.Potential diagnostic and prognostic biomarkers for cholangiocarcinoma in serum and bile.Value of brush cytology for optimal timing of liver transplantation in primary sclerosing cholangitis.Mucinous cholangiocarcinoma: Clinicopathological features of the rarest type of cholangiocarcinoma.Biomarkers for the Diagnosis of Cholangiocarcinoma: A Systematic Review

P2860

Q26767120-33ED1A5A-F28D-41DC-9AFE-6B51A6CEF19C Q26775370-7A68577C-08A7-4D7F-9C63-3810A4B5069A Q30493559-C758EB6A-6AE2-4E55-B060-E8FE3227B841 Q33945955-5F9F7092-E09C-4961-B546-E9D98A6E25D2 Q33966083-38D00FA7-EBE8-45EB-91A3-AD1598255692 Q34127295-6E055947-27E8-4892-81D3-FE6A4E5963DA Q34382675-AF7C7F04-58F4-406E-9588-FC2F101EF2E8 Q34391135-E2B3EA99-2AFD-43C9-BAAE-941F754724CC Q34544953-93A115D4-DC8A-469D-9F36-9EC00D89CCA2 Q34732888-F92E68A1-F817-4927-9DCA-06F38EA6A9EF Q35039581-B5A1A478-C2B3-4CDB-9FBC-1B6D5B03841D Q35654552-39CEFFBF-9195-4CEC-8495-B0C396B53AD7 Q35962107-3EBFD959-0470-4590-98DA-AF7C34C0F756 Q36151669-7083DB74-76B0-46B1-9268-F27D2E7CC77C Q36306293-29B369AA-69E9-4C2C-9A6C-20B757F0B8C1 Q36866777-E2C6CD24-96E6-4B4E-93A2-C481F2384F4C Q36900063-186E9781-D0FE-41CB-9CD7-91D5BB5F04DC Q37082378-69EA9603-A7DD-4670-A428-36F6D94BE5A7 Q37344239-F82ED3E8-097D-46B2-A6FC-E702E91FD2FD Q37347327-20DBDD64-7351-4F97-A255-ACF50B968914 Q37777156-2BC31F63-54BE-4A04-8258-17CEDFDF5547 Q37799533-8BEBE3FB-D9B2-4557-8096-27B2BBA785C3 Q37832697-EE1FFDC9-AF26-492A-8E5C-67DB266B4C25 Q37957967-C341EC26-FE70-4F76-8E13-FEFAD6B0B1AE Q38001365-DC7D7F20-CB7C-4130-AAA8-5FAAF8666EB9 Q38076736-6CD2B2E8-E15C-4DC8-8B97-DF5EE60541CB Q38189751-732795EE-D6A1-4E45-AEE0-E3AC4CD1CD9F Q38623360-0F77264D-EDD9-4760-864F-F57D8F0C7E8A Q40355263-1D80DFB2-EAE8-4CAC-BEDB-8EFBF76A8F30 Q40413572-0CF4035C-BB9E-4CD9-90FD-E7BFBC11C996 Q44096896-FD686CA8-20D7-48C4-8FF9-B3EB3D5679A1 Q45159737-DE4CCD8C-92CA-4A7D-BD83-0EF29F5A7AD7 Q48222619-B581A4B6-5043-46F1-B3D6-FDBFBF358037 Q50906670-02798870-AA10-4165-A786-560122F04CC8 Q50940059-21B0755A-BDB4-4298-9B2E-F72F5C960F09 Q51314955-345639F7-801C-4E5C-BC75-5E020740C135 Q52774253-48FD10F4-3049-485A-9AC8-6BC75EA41692 Q55120073-BB7DF60E-0DD0-41E2-AB90-FCDEB01F5BC3 Q56379222-924E3296-EBC7-4959-A1ED-3FBF37281E28

P2860

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

http://www.wikidata.org/entity/Q33959857

description

2002 nî lūn-bûn

@nan

2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

@ast

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

@en

type

label

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

@ast

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

@en

prefLabel

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

@ast

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

@en

P1433

Q33959857-A3B4220A-55B4-4417-9FD3-03AE73B59EE0

P1476

Q33959857-E89FCA95-013E-4CEE-8033-3B000EFAC9CF

P2093

Q33959857-1E29409A-3775-4DF5-9E93-6F30FC3594FD

Q33959857-69D62D2D-6477-4989-B906-11A3A6919EC0

Q33959857-718D62AE-BCDE-40C8-8FA5-15D0A5F54D47

Q33959857-8FBACE9F-83F5-4754-B33B-8E1214F05093

Q33959857-A0E5378F-655F-40D1-8842-0B173EFCD97F

Q33959857-A109B4CD-BE64-4E7A-B6C4-05B05BF3B2EC

Q33959857-B6F6D5D4-3EF4-4A10-AA93-FF044F2F2E1A

Q33959857-D7993237-2146-4A9D-A47A-E8E4D5DEF8A4

Q33959857-D8CB0610-B62B-41CF-864D-FEBA10D5588F

P304

Q33959857-F2E33683-D14A-4F81-8B2A-1902D3C95003

P31

Q33959857-D44AC0B1-E1E9-4A50-BB0C-87D4B60E2F03

P356

Q33959857-8E554BF5-8306-4CC3-93D1-79112BB59935

P407

Q33959857-A5515526-A91B-4812-854B-43913CA343D2

P433

Q33959857-0674E952-5561-4106-963F-E898E03F6A0C

P478

Q33959857-8FB1AF44-E45D-4E4D-B4D8-8097F83419E7

P577

Q33959857-3143EAA3-79D2-4006-813A-C6F3E124AA49

P698

Q33959857-7C3FC8D5-80DA-4B23-B4AC-A036FDC07F49

P921

Q33959857-222A0BCD-9451-40CA-932B-161B4690A393

Q33959857-7DA8BB92-79CF-4635-9988-3DF6860B69E8

P356

MGE.2002.125105

P1433

Gastrointestinal Endoscopy

P1476

Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.

@en

P2093

Adam Slivka

http://www.w3.org/2001/XMLSchema#string

Eduardo Siqueira

http://www.w3.org/2001/XMLSchema#string

Joel L Weissfeld

http://www.w3.org/2001/XMLSchema#string

John Martin

http://www.w3.org/2001/XMLSchema#string

Juan R Madariaga

http://www.w3.org/2001/XMLSchema#string

Kareem Abu-Elmaagd

http://www.w3.org/2001/XMLSchema#string

Mordechai Rabinovitz

http://www.w3.org/2001/XMLSchema#string

Robert E Schoen

http://www.w3.org/2001/XMLSchema#string

William Silverman

http://www.w3.org/2001/XMLSchema#string

P304

40-47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1067/MGE.2002.125105

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12085033

http://www.w3.org/2001/XMLSchema#string

P921

cholangiocarcinoma